EntreMed Announces its Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models.

0 Comments | M2 Presswire, June, 2007

M2 PRESSWIRE-1 June 2007-Headline Maker: EntreMed Announces its Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:01062007 Market Gainer is quickly emerging as the one stop shop for international small-cap investors looking to stay a step ahead of the markets.

Activity on the NASDAQ market has brought this company to the attention of our research team. EntreMed, Inc. (Nasdaq: ENMD), is responding to the attention of investors. Our goal is to create a community of international investors who consistently and effectively capitalize on the enormous gains the small-cap Canadian and American exchanges offer. June 1 - EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing...